References

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

10.1056/nejmoa1105185 · 2011 · External reference

Unresolved reference

External reference

Current causes of death in children and adolescents in the United States

10.1056/nejmc2201761 · 2022 · External reference

Children’s Oncology Group’s 2013 blueprint for research: survivorship and outcomes

10.1002/pbc.24422 · 2013 · External reference

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study

10.1200/jco.2007.13.8925 · 2009 · External reference

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

10.1038/nature25795 · 2018 · External reference

The genomic landscape of pediatric cancers: Implications for diagnosis and treatment

10.1126/science.aaw3535 · 2019 · External reference

Mutational heterogeneity in cancer and the search for new cancer-associated genes

10.1038/nature12213 · 2013 · External reference

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

10.1038/ng.3333 · 2015 · External reference

Mutational dynamics between primary and relapse neuroblastomas

10.1038/ng.3349 · 2015 · External reference

The landscape of genomic alterations across childhood cancers

10.1038/nature25480 · 2018 · External reference

A first-generation pediatric cancer dependency map

10.1038/s41588-021-00819-w · 2021 · External reference

Epigenetic changes in pediatric solid tumors: promising new targets

10.1158/1078-0432.ccr-11-1921 · 2012 · External reference

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

10.1038/nm.4439 · 2018 · External reference

Divergent clonal selection dominates medulloblastoma at recurrence

10.1038/nature16478 · 2016 · External reference

Genomic ALK alterations in primary and relapsed neuroblastoma

10.1038/s41416-023-02208-y · 2023 · External reference

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

10.1038/ng.3438 · 2015 · External reference

BRAF alterations in primary brain tumors

2018 · External reference

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

10.1038/28212 · 1998 · External reference

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

10.1172/jci64400 · 2012 · External reference

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

10.1038/nature10833 · 2012 · External reference

DNA methylation-based classification of central nervous system tumours

10.1038/nature26000 · 2018 · External reference

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma

10.1056/nejmoa1411087 · 2015 · External reference

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

10.1016/j.ejca.2017.09.032 · 2017 · External reference

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

10.1016/j.annonc.2020.07.002 · 2020 · External reference

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

10.1200/jco.2017.73.4830 · 2017 · External reference

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

10.2147/dddt.s147384 · 2018 · External reference

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Study (ADVL0912)

10.1158/1078-0432.ccr-20-4224 · 2021 · External reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

10.1056/nejmoa0911123 · 2010 · External reference

Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients

1984 · External reference

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

10.1016/s1470-2045(18)30578-3 · 2018 · External reference

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

10.1001/jamaoncol.2015.5689 · 2016 · External reference

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

10.1158/1078-0432.ccr-17-0381 · 2017 · External reference

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

10.1038/s41591-020-1072-4 · 2020 · External reference

Precision medicine in pediatric oncology

10.1097/mop.0000000000000570 · 2018 · External reference

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial

10.1200/jco.21.02838 · 2022 · External reference

Target and Agent Prioritization for the Children’s Oncology Group-National Cancer Institute Pediatric MATCH Trial

10.1093/jnci/djw274 · 2017 · External reference

10.1016/j.ejca.2021.03.032

10.1016/j.ejca.2021.03.032 · 2021 · External reference

Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis

10.3109/08880018.2014.947009 · 2014 · External reference

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?

10.1007/s00383-012-3109-3 · 2012 · External reference

A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era

10.1158/2159-8290.cd-21-1094 · 2022 · External reference

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies

10.1158/2326-6066.cir-19-0692 · 2020 · External reference

Neuroblastoma

10.1038/nrdp.2016.78 · 2016 · External reference

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

10.1200/jco.2008.16.6785 · 2009 · External reference

Advances in emerging drugs for the treatment of neuroblastoma

10.1080/14728214.2017.1294159 · 2017 · External reference

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project

10.1200/jco.2010.34.3392 · 2011 · External reference

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

10.3389/fonc.2020.01000 · 2020 · External reference

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

10.1158/1078-0432.ccr-20-3909 · 2021 · External reference

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

10.1200/jco.20.00203 · 2020 · External reference

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

10.4161/onci.19864 · 2012 · External reference

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission

10.1158/1078-0432.ccr-13-1012 · 2014 · External reference

Long path to MYC inhibition approaches clinical trials

10.1038/s41568-019-0141-9 · 2019 · External reference

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study

10.1200/jco.1998.16.6.2007 · 1998 · External reference

Targeting of the MYCN protein with small molecule c-MYC inhibitors

10.1371/journal.pone.0097285 · 2014 · External reference

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells

10.1186/s12935-019-1072-y · 2020 · External reference

ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma

10.1158/0008-5472.can-07-6866 · 2008 · External reference

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

10.1158/2159-8290.cd-12-0418 · 2013 · External reference

Modelling Myc inhibition as a cancer therapy

10.1038/nature07260 · 2008 · External reference

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene

10.1128/mcb.00248-19 · 2019 · External reference

Direct MYC Inhibitor Passes First Clinical Test

10.1158/2159-8290.cd-nb2022-0067 · 2023 · External reference

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study

10.1016/s1470-2045(13)70095-0 · 2013 · External reference

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma

10.1002/ijc.30440 · 2017 · External reference

Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways

10.18632/oncotarget.10070 · 2016 · External reference

The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway

10.1038/onc.2009.80 · 2009 · External reference

RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma

10.1158/0008-5472.can-18-1045 · 2018 · External reference

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53

10.1093/jnci/djp355 · 2009 · External reference

Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis

10.1016/j.bmcl.2013.08.018 · 2013 · External reference

Absence of p53 gene mutations in primary neuroblastomas

1993 · External reference

Reactivation of p53 via MDM2 inhibition

10.1038/cddis.2015.302 · 2015 · External reference

Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis

10.1093/jnci/djp376 · 2009 · External reference

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma

10.1038/cddiscovery.2015.26 · 2015 · External reference

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma

10.1007/s10456-011-9210-8 · 2011 · External reference

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report

10.1200/jco.2009.25.9119 · 2010 · External reference

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

10.1158/1078-0432.ccr-15-1449 · 2016 · External reference

Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs

2015 · External reference

Wilms tumor: "State-of-the-art" update, 2016

10.1053/j.sempedsurg.2016.09.003 · 2016 · External reference

Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration

10.1200/jco.2015.62.1888 · 2015 · External reference

Systematic review of the immunological landscape of Wilms tumors

10.1016/j.omto.2021.06.016 · 2021 · External reference

Relationship of tumour-associated macrophages with poor prognosis in Wilms’ tumour

10.1016/j.jpurol.2020.03.016 · 2020 · External reference

Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in Wilms tumors

10.1016/j.tranon.2014.05.008 · 2014 · External reference

Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors

10.1002/pbc.26613 · 2017 · External reference

Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy

10.1080/08880018.2019.1578843 · 2019 · External reference

Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells

10.1002/cjp2.152 · 2020 · External reference

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial

10.1016/s1470-2045(19)30671-0 · 2020 · External reference

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

10.1158/1078-0432.ccr-18-0432 · 2019 · External reference

Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry

10.2350/08-10-0544.1 · 2010 · External reference

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

10.1002/pbc.25631 · 2015 · External reference

Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor

10.1097/cji.0b013e3181826d72 · 2008 · External reference

Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children’s Cancer Group study

10.1097/00002371-199408000-00006 · 1994 · External reference

Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012

10.1093/jncics/pkz007 · 2019 · External reference

Cancer Statistics, 2021

2021 · External reference

Risk of hepatoblastoma in familial adenomatous polyposis

10.1016/s0022-3476(05)80297-5 · 1991 · External reference

Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry

10.1016/s0022-3476(98)70008-3 · 1998 · External reference

Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups

10.1002/hep.28888 · 2017 · External reference

New insights into diagnosis and therapeutic options for proliferative hepatoblastoma

10.1002/hep.29672 · 2018 · External reference

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

10.1016/j.jhep.2020.03.025 · 2020 · External reference

Wnt/β-Catenin Signaling in Liver Cancers

10.3390/cancers11070926 · 2019 · External reference

Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice

10.1002/hep.28975 · 2017 · External reference

Current therapeutic strategies for childhood hepatic tumors: surgical and interventional treatments for hepatoblastoma

10.1007/s10147-013-0625-7 · 2013 · External reference

Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts

10.1038/bjc.2012.539 · 2013 · External reference

Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy

10.1007/s11912-022-01230-2 · 2022 · External reference

Activation of phosphatidylinositol-3’-kinase/AKT signaling is essential in hepatoblastoma survival

10.1158/1078-0432.ccr-08-2878 · 2009 · External reference

Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients

10.1016/j.ejca.2011.12.032 · 2012 · External reference

Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma

10.18632/oncotarget.25205 · 2018 · External reference

Transforming growth factor-beta1-induced Smad signaling, cell-cycle arrest and apoptosis in hepatoma cells

10.1093/carcin/22.3.447 · 2001 · External reference

Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas

10.1007/s100380300008 · 2003 · External reference

Volasertib preclinical activity in high-risk hepatoblastoma

10.18632/oncotarget.27237 · 2019 · External reference

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models

10.1002/hep.31919 · 2021 · External reference

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

10.1038/s41598-021-82542-4 · 2021 · External reference

Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma

10.4161/onci.22620 · 2013 · External reference

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

10.1002/cncr.24465 · 2009 · External reference

Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV

10.1200/jco.2003.06.129 · 2003 · External reference

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report

10.1002/pbc.24532 · 2013 · External reference

Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma

10.1038/sj.onc.1204599 · 2001 · External reference

RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy

10.1016/j.jconrel.2016.05.063 · 2016 · External reference

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma

10.1126/scisignal.aau7632 · 2018 · External reference

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

10.1016/j.ejca.2011.09.021 · 2012 · External reference

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group

10.1200/jco.19.00576 · 2019 · External reference

10.1016/j.ejca.2018.02.011

10.1016/j.ejca.2018.02.011 · 2018 · External reference

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group

10.1002/pbc.24605 · 2014 · External reference

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group

10.1002/cncr.31770 · 2019 · External reference

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group

10.1002/pbc.25334 · 2015 · External reference

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children’s Oncology Group

10.1002/pbc.25548 · 2015 · External reference

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

10.1200/jco.2002.20.3.776 · 2002 · External reference

Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum

1988 · External reference

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma

10.1016/j.celrep.2014.03.003 · 2014 · External reference

Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma

10.18632/oncotarget.18236 · 2017 · External reference

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

10.1200/jco.2014.59.4895 · 2015 · External reference

Novel Immunotherapies for Osteosarcoma

10.3389/fonc.2022.830546 · 2022 · External reference

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions

10.1080/2162402x.2020.1747677 · 2020 · External reference

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

10.1002/cncr.28461 · 2014 · External reference

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

10.1002/pbc.25688 · 2016 · External reference

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

10.1002/pbc.25099 · 2014 · External reference

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children’s Oncology Group

10.1016/j.ejca.2019.08.015 · 2019 · External reference

Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells

10.1242/jcs.094029 · 2012 · External reference

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

10.1136/jitc-2020-000798 · 2020 · External reference

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma

10.1016/j.jbo.2020.100332 · 2020 · External reference

Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis

10.1016/j.jbo.2021.100362 · 2021 · External reference

Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells

10.1038/s41401-019-0262-4 · 2019 · External reference

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

10.1038/onc.2014.314 · 2015 · External reference

Unresolved reference

2008 · External reference

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth

10.1001/jama.2015.10080 · 2015 · External reference

Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study

10.1016/j.ejca.2016.06.009 · 2016 · External reference

Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas

10.1016/j.ijrobp.2010.07.024 · 2011 · External reference

Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients

10.1007/s40264-014-0139-x · 2014 · External reference

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

10.1097/tp.0b013e318192dd56 · 2009 · External reference

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

10.2147/ott.s166151 · 2018 · External reference

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

10.1200/jco.18.02374 · 2019 · External reference

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

10.1038/s41587-021-00857-z · 2021 · External reference

Blood-Derived Liquid Biopsies Using Foundation One(®) Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience

10.3390/cancers14112774 · 2022 · External reference

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

10.1038/s43018-020-0096-5 · 2020 · External reference

Analysis of circulating tumor DNA to monitor metastatic breast cancer

10.1056/nejmoa1213261 · 2013 · External reference

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

10.1038/s41591-019-0407-5 · 2019 · External reference

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

10.1186/s13073-021-00969-w · 2021 · External reference